Risk factors
OS Therapies (OSTX) risk factors
Item 1A of every OS Therapies Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors52 risks11 new8 dropped13 reworded
OSTX focuses on clinical development of OST-HER2 for rare Osteosarcoma, facing patient enrollment hurdles and capital constraints.
Filed Mar 31, 2026 - FY2024 10-K risk factors49 risks
OSTX focuses entirely on developing immunotherapy candidates OST-HER2 and OST-tADC, facing going-concern doubts, zero revenues, and heavy reliance on key executives Paul A. Romness and Robert G. Petit with only four full-time employees.
Filed Mar 31, 2025